IP Library Granted Patent US 12,629,423
Granted Patent B2
US 12,629,423 · App. 19/083,361 · Granted May 19, 2026

Olfactory delivery scaffolds using antisense oligonucleotides and methods for making and using same

Inventors: Kelvin Cooper (Sarasota, FL); Parnian Lak (Mountain View, CA); Renaud Renault (Emeryville, CA)
Assignee: Olfera Corporation
A61K47/543A61K9/0043C07C219/08C07C235/28C07C237/08C07C271/16C07C271/24C07D295/088C07F9/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,629,423
App. No.
19/083,361
Granted
May 19, 2026
Kind
B2
Abstract

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and/or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and/or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and/or neurodegenerative diseases.

Claims (9)

1 . An olfactory delivery scaffold compound which provides an olfactory targeting component, a linker and a therapeutic component, wherein the olfactory delivery scaffold compound is a compound of Formula (G)

wherein R is selected from the group consisting of

wherein the * symbol marks a carbon atom that attaches by a bond to the remaining compound,

wherein X is O or NH,

wherein ASO is an antisense oligonucleotide attached at the 3′ or 5′ position.

2 . The compound of claim 1 , wherein R is

3 . The compound of claim 1 , wherein R is

4 . The compound of claim 1 , wherein R is

5 . The compound of claim 1 , wherein R is

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2026
From: RENAULT, RENAUD
To: OLFERA CORPORATION
Reel/Frame 074146/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2026
From: RENAULT, RENAUD
To: OLFERA CORPORATION
Reel/Frame 073852/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2026
From: LAK, PARNIAN
To: OLFERA CORPORATION
Reel/Frame 073553/0827 →
Continuity (3)
Continuation PCTUS2024052459 · Oct 22, 2024
Provisional Application 63546506 · Oct 30, 2023
Related Publication 20250269038A1 · Aug 28, 2025
References Cited (17)
US 8299062B2 · Volvovitz · 2012 [cited by applicant]
US 20140364330A1 · Mershin et al. · 2014 [cited by applicant]
US 20190055511A1 · Villard et al. · 2019 [cited by applicant]
US 20200392490A1 · Ziv · 2020 [cited by examiner]
US 20210113558A1 · Gendelman · 2021 [cited by applicant]
US 20220340849A1 · Pediaditakis et al. · 2022 [cited by applicant]
US 20250249106A1 · Cooper · 2025 [cited by examiner]
WO 2005102275A2 · 2005 [cited by applicant]
WO 2018237302A1 · 2018 [cited by applicant]
WO 2022239001A1 · 2022 [cited by applicant]
WO 2025076268A1 · 2025 [cited by applicant]
WO 2025096244A1 · 2025 [cited by applicant]
Ertural et al., RNA Therapeutics: Focus on Antisense Oligonucleotides in the Nervous System. Biomol Ther (Seoul). Jul. 1, 2025;33(4):572-581. doi: 10.4062/biomolther.2025.022. Epub Jun. 19, 2025. (Year: 2025). [cited by examiner]
International Search Report from Appl. No. PCT/US2024/052459, mailed on Jan. 31, 2025. [cited by applicant]
Kuhns et al., Characterizing novel olfactory receptors expressed in the murine renal cortex, Am J Physiol Renal Physiol, (2019), 317:F172-F186. [cited by applicant]
Office Action from U.S. Appl. No. 19/083,391, mailed on Sep. 25, 2025. [cited by applicant]
Sarukhanyan et al., In Silico Designed Axl Receptor Blocking Drug Candidates Against Zika Virus Infection, ACS Omega, (2018), 5281-5290. [cited by applicant]